MedPath

A multicentre randomised controlled trial of low versus high threshold treatment in preterm infants with progressive posthaemorrhagic ventricular dilatatio

Completed
Conditions
Posthaemorrhagic ventricular dilatation
Pregnancy and Childbirth
Intracranial nontraumatic haemorrhage of fetus and newborn
Registration Number
ISRCTN43171322
Lead Sponsor
Erasmus Medical Centre (Netherlands)
Brief Summary

2018 results in https://www.ncbi.nlm.nih.gov/pubmed/29440132

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
125
Inclusion Criteria

Current inclusion criteria as of 03/01//2012
Premature infants with:
1. A gestational age equal to or below 34 weeks
2. An intraventricular haemorrhage grade III according to Volpe (>50% of the ventricle) and grade IV haemorrhage
3. A progressive posthaemorrhagic ventricular enlargement above the 97th centile for gestational age according to Levene and a diagonal width enlargement of the frontal horn above 6 mm according to Davies

Previous inclusion criteria
Premature infants with:
1. A gestational age equal to or below 34 weeks
2. An intraventricular haemorrhage grade III according to Volpe (>50% of the ventricle)
3. A progressive posthaemorrhagic ventricular enlargement above the 97th centile for gestational age according to Levene and a diagonal width enlargement of the frontal horn above 6 mm according to Davies

Exclusion Criteria

Current exclusion criteria as of 03/01//2012
1. Congenital cerebral malformation
2. Periventricular leucomalacia > grade II according to de Vries
3. Posthaemorrhagic ventricular dilatation already present at birth
4. Central nervous system infection
5. Metabolic disease

Previous exclusion criteria
1. Congenital cerebral malformation
2. Cerebral parenchymal haemorrhage
3. Periventricular leucomalacia > grade II according to de Vries
4. Posthaemorrhagic ventricular dilatation already present at birth
5. Central nervous system infection
6. Metabolic disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath